Exagen Inc. And Johns Hopkins University Announce License Agreement For Novel Patented Lupus Nephritis Biomarkers
Portfolio Pulse from Benzinga Newsdesk
Exagen Inc. (NASDAQ:XGN) and Johns Hopkins University have announced an exclusive license agreement for the development of novel patented biomarkers for therapeutic management of patients with lupus nephritis. Exagen will acquire a worldwide exclusive license to an invention from the laboratory of Michelle Petri, MD, MPH, and Andrea Fava, MD. The company plans to develop these biomarkers into assays to aid diagnostic and treatment decisions.
November 09, 2023 | 10:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Exagen's partnership with Johns Hopkins University for the development of novel patented biomarkers for lupus nephritis could potentially enhance the company's product portfolio and strengthen its position in the autoimmune testing solutions market.
The partnership with Johns Hopkins University could potentially enhance Exagen's product portfolio and strengthen its position in the autoimmune testing solutions market. The development of novel patented biomarkers for lupus nephritis could provide unique clinical insight into a specific patient's lupus nephritis in a non-invasive manner, which could be a significant advancement in the field.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100